NCT00981630View on ClinicalTrials.gov

Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

November 30, 2007

Conditions
Japanese Encephalitis
Interventions
BIOLOGICAL

Live attenuated Japanese encephalitis virus

0.5 mL,Subcutaneous

BIOLOGICAL

Live attenuated Japanese encephalitis virus

0.5 mL, Subcutaneous

BIOLOGICAL

Live attenuated Japanese encephalitis virus

0.5 mL, Subcutaneous

BIOLOGICAL

ChimeriVax™ diluent (Placebo)

0.5 mL, Subcutaneous

Trial Locations (2)

5000

Adelaide

QLD 4006

Herston

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY